TITLE

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

AUTHOR(S)

Benmessaoud, Dalila; Hamdani, Nora; Boni, Claudette; Ramoz, Nicolas; Hamon, Michel; Kacha, Farid; Gorwood, Philip

PUB. DATE

January 2008

SOURCE

BMC Psychiatry;2008, Vol. 8, Special section p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: The -1438A/G polymorphism of the 5-HT2A gene has been found to be associated with clinical response to clozapine and other second generation antipsychotics. Testing the impact of this marker on response to first generation antipsychotics (which have a lower affinity for the 5-HT2A receptor) provides the opportunity to help disentangling the two different roles that this polymorphism might have. A psychopharmacogenetic role should be detected only for antipsychotics with high affinity to the 5-HT2A receptor (therefore to second generation antipsychotics). An alternative role would imply tagging a subgroup of patients responsive to any antipsychotic, whatever their affinity, meaning that the association is more depending on non pharmacological charaterictics, such as clinical specificities. Methods: A family-based sample of 100 Algerian patients with schizophrenia (according to DSM-IV criteria) and their 200 biological parents was recruited, in order to avoid stratification biases. Patients were all treated, or have been treated, by conventional antipsychotics (mainly haloperidol) for at least four weeks, at appropriate dosage. May and Dencker scale was used to distinguish responders and non responders. Results: No allele of the -1438A/G polymorphism of the 5-HT2A gene was transmitted in excess (50 transmitted for 38 untransmitted) in the whole sample of patients with schizophrenia (p = .90). In contrast, a significant excess of transmission of the G allele was observed (p = .02) in the subgroup of patients with good treatment response (17 transmitted for 6 untransmitted). Conclusion: Using a TDT approach, we showed that the G allele of the -1438A/G polymorphism of the gene coding for the 5-HT2A receptor was associated to schizophrenia with good response to conventional antipsychotics, although this conclusion is based on 88 informative patients only. Because previous data showed the same result with atypical antipsychotics, it can be concluded that the G allele tags a subgroup of schizophrenic patients with greater chance of improvement with antipsychotics of either type.

ACCESSION #

35702796

 

Related Articles

• Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Nikolac Perkovic, Matea; Nedic Erjavec, Gordana; Zivkovic, Maja; Sagud, Marina; Uzun, Suzana; Mihaljevic-Peles, Alma; Kozumplik, Oliver; Muck-Seler, Dorotea; Pivac, Nela // Psychopharmacology;Sep2014, Vol. 231 Issue 18, p3757 

  Rationale: Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system. There are mixed reports about the association between the BDNF Val66Met...

• Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Liou, Y-J; Bai, Y M; Lin, E; Chen, J-Y; Chen, T-T; Hong, C-J; Tsai, S-J // Pharmacogenomics Journal;Feb2012, Vol. 12 Issue 1, p54 

  The use of atypical antipsychotics (AAPs) is associated with increasing the risk of the metabolic syndrome (MetS), which is an important risk factor for cardiovascular disease and diabetes. Two insulin-induced gene (INSIG) isoforms, designated INSIG-1 and INSIG-2 encode two proteins that mediate...

• Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Hwang, Rudi; Shinkai, Takahiro; De Luca, Vincenzo; Müller, Daniel J.; Xingqun Ni; Macciardi, Fabio; Potkin, Steven; Lieberman, Jeffrey A.; Meltzer, Herbert Y.; Kennedy, James L. // Psychopharmacology;Aug2005, Vol. 181 Issue 1, p179 

  Dopamine D2 receptor blockade is the major basis for the antipsychotic action of typical antipsychotic drugs (AP) and a necessary but not sufficient basis for the antipsychotic action of atypical APs such as clozapine and other multireceptor antagonists which rely, in part, upon 5-HT2A...

• CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. Balibey, Hakan; Basoglu, Cengiz; Lundgren, Stefan; Babaoglu, Melih O.; Yasar, Umit; Herken, Hasan; Rane, Anders; Bozkurt, Atilla; Cetin, Mesut // Klinik Psikofarmakoloji Bulteni;Jun2011, Vol. 21 Issue 2, p93 

  Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or occurrence of side effects of antipsychotic drugs. Aim: We studied the association of response to clozapine treatment in schizophrenic patients in relation to polymorphisms in the CYP1A2 gene....

• A translational research approach to poor treatment response in patients with schizophrenia: clozapine--antipsychotic polypharmacy. Honer, William G.; Procyshyn, Ric M.; Chen, Eric Y. H.; MacEwan, G. William; Barr, Alasdair M. // Journal of Psychiatry & Neuroscience;Nov2009, Vol. 34 Issue 6, p433 

  Poor treatment response in patients with schizophrenia is an important clinical problem, and one possible strategy is concurrent treatment with more than one antipsychotic (polypharmacy). We analyzed the evidence base for this strategy using a translational research model focused on...

• Schizophrenia and autoantibodies against the regulatory peptide 5HT-modulin. Ashmarin, I. P.; Burbaeva, G. Sh.; Danilova, R. A.; Obukhova, M. F. // Doklady Biological Sciences;Feb2007, Vol. 412 Issue 1, p18 

  The article presents a study carried out to measure the level of autoantibodies against the neuroregulator peptide 5HT-modulin in schizophrenics, and examine the effect of treatment on this parameter. In the study, titers of anti-5HT-modulin autoantibodies were measured in patients having...

• IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Küfferle, B.; Tauscher, Johannes; Asenbaum, Susanne; Vesely, Christine; Podreka, I.; Brücke, Thomas; Kasper, Siegfried // Psychopharmacology;1997, Vol. 133 Issue 4, p323 

  Abstract We investigated the striatal dopamine-2 (D[sub 2]) receptor occupancy caused by different antipsychotic substances in 18 psychotic patients (16 with schizophrenic and two with schizoaffective disorder according to DSM-IV) with single photon emission computed tomography (SPECT) using...

• Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Smith, R. C.; Segman, R. H.; Golcer-Dubner, T.; Pavlov, V.; Lerer, B. // Pharmacogenomics Journal;2008, Vol. 8 Issue 3, p228 

  Schizophrenic patients who are treated with antipsychotics, especially second generation antipsychotics, such as clozapine and olanzapine, manifest an increase in cholesterol and triglycerides as well as other changes associated with diabetes or the metabolic syndrome. Previous studies have...

• Selective acquired long QT syndrome (saLQTS) upon risperidone treatment. Lazarczyk, Maciej Jakub; Bhuiyan, Zahir A; Perrin, Nicolas; Giannakopoulos, Panteleimon // BMC Psychiatry;2012, Vol. 12 Issue 1, p220 

  Background: Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger the acquired long QT syndrome (aLQTS). All of them are thought to act at the level of KCNH2, a subunit of the potassium channel. Although the QT-prolonging drugs are proscribed in the...

Read the Article